Start-Up Quarterly Statistics, Q2 2009
This article was originally published in Start Up
Highlights from the Q2 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $864 million--a 25% increase from Q1 2009--with most of the money, 54% or $465 million, coming out of the device industry, which saw only $127 million the previous quarter. There was one acquisition--PPD paid $14.5 million in cash for Magen BioSciences. In the most significant alliance, valued at up to $527 million, GSK got rights to three compounds from Concert Pharmaceuticals, including two in the preclinical stage, which was the most popular phase of development on Q2 alliances.
You may also be interested in...
Small Bone Innovations and ConforMIS drew capital from across the globe for their $144 million and $50 million financings.
Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?
This year's annual Biotechnology Industry Organization was chock-full of angst, with biotech clearly in a contraction amid bankruptcies, scarce financing, and few exits in sight. START-UP was there to chronicle some of the technological and financial highlights, to gauge the pulse of industry, and to talk to a variety of biotech and pharmaceutical executives about the future of biotech dealmaking. Snapshots here include the unveiling of Adimab's platform, the NIH's new bridge funding option; and a positive message on anti-infectives development . More of our BIO coverage can be found on The IN VIVO Blog (http://invivoblog.blogspot.com).